Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Anke Biotech is a prominent Chinese biopharmaceutical company focused on the research, development, and commercialization of recombinant DNA products and diagnostic reagents. The company is a market leader in China for its flagship products, Ansomone (recombinant human growth hormone) and Anterferon (recombinant human interferon alpha-2b), which address endocrine disorders and viral infections. Anke Biotech has strategically expanded its portfolio into oncology and precision medicine, developing a pipeline of monoclonal antibodies and advanced cell therapies like CAR-T. Listed on the Shenzhen Stock Exchange since 2009, the company operates extensive GMP-certified manufacturing facilities in Hefei. Its business model integrates traditional biopharmaceuticals with modern genomic diagnostics and forensic services.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Anke Biotech.